Inventiva S.A.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-09-25upcoming | — | — | — |
| 2022-03-10 | -0.39 | -0.16 | +58.21% |
| 2020-09-16 | -0.45 | -0.21 | +52.31% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IVA | -0.80% | -19.05% | +6.02% | +45.43% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.77% | -14.41% | +9.46% | +32.74% |